araag2/HINT huggingface dataset:
Clinical trial NCT02899988 (phase 2, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: mirikizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of
             chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the
             following criteria:

               -  plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score
                  ≥12 in affected skin at screening and baseline

               -  sPGA score of ≥3 at screening and baseline

          -  Candidate for biologic treatment for psoriasis.

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other
             serious and/or unstable illness that, in the opinion of the investigator, could
             constitute a risk when taking investigational product or could interfere with the
             interpretation of data.

          -  Breastfeeding or nursing (lactating) women.

          -  Have had serious, opportunistic, or chronic/recurring infection within 6 months prior
             to screening.

          -  Have received live vaccine(s) (included attenuated live vaccines) within 1 month of
             screening or intend to during the study.

          -  Have any other skin conditions (excluding psoriasis) that would affect interpretation
             of the results.

          -  Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days
             prior to baseline.

          -  Have received topical psoriasis treatment within 14 days prior to baseline.

          -  Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17
             targeting biologics within 8 weeks prior to baseline.

          -  Have previous exposure to any biologic therapy targeting IL-23 (including
             ustekinumab), either licensed or investigational (previous briakinumab use is
             permitted).
Clinical trial NCT02900131 (phase 2, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: jaungo, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. The diagnosis of AD will be made according to the criteria of Hanifin and Rajka

          2. Age: 5 years to 65 years

          3. objective SCORAD ≦40, Diagnosis of Mild to Moderate Atopic Dermatitis (AD)

          4. Exoriation≥1, Lichenification≥1, Dryness≥1 or Exoriation+Lichenification+Dryness≥3

          5. Participants who able to express intention

          6. Participants willing to provide written informed consent

        Exclusion Criteria:

          1. Participants have oozing in the lesion

          2. Users of following medications prior to trial periods

             ① Oral steroids, immunosuppressants and antibiotics within 4 weeks prior to this trial

             ② Topical steroids, immunosuppressants and antibiotics within 2 weeks prior to this
             trial

             ③ Light therapy within 2 weeks prior to this trial

             ④ Other medications thought to be inappropriate by researchers

          3. Participants have severe burn or wide wound

          4. Participants have oozing or ulcer in the lesion

          5. Allergic reactions to Angelica gigas, Siebold et Zuccarini, sesame oil and lard

          6. Participants have skin disease except atopic dermatitis

          7. Participants have severe renal function disease (sCr > 2.0 mg/dL)

          8. Participants have severe liver function disease (ALT, AST, ALP ≥ 2.5 × normal limits)

          9. Participants have uncontrolled chronic diseases

         10. Pregnancy, lactation

         11. Participation in another clinical trial within one month of enrolment

         12. Underlying disease or history of severe disease, abnormal state (paralysis; mental
             retardation other emotional or mental problems; diseases that can affect the
             absorption of drugs; no enough time to participate in this trial; visual disturbance
             and hearing impairment; inability to understand written consent or engage in this
             study)

         13. Judgment by experts that the potential subject's participation is inappropriate.
Clinical trial NCT02906579 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, hypertension
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: matching placebo, iw-1973
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is ambulatory male or female

          -  Patient's body mass index score is >20 and <40 kg/m2 at the Screening Visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             check-in and must agree to use double-barrier contraception throughout the duration of
             the study

          -  Patient's health is stable with no clinically significant findings on a physical
             examination

          -  Patient has type 2 (ie adult onset) diabetes mellitus diagnosed by a physician or
             nurse practitioner > 6 months before the Screening Visit, and an entry HbA1c that does
             not mandate prompt intervention for improved control

          -  Patient has hypertension diagnosed by a physician or nurse practitioner > 6 months
             before the Screening Visit and BP within the protocol's acceptable range

          -  Patients must be on a stable regimen for glycemic control, and a stable regimen for
             hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi)
             or angiotensin receptor blocker (ARB)

          -  Patient has abnormal endothelial function measured by the EndoPAT

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Patient has a clinically significant active or unstable medical condition that, in the
             opinion of the Investigator, would preclude trial participation

          -  Patient is on medication(s) that when co-administered with a soluble guanylate cyclase
             (sGC) stimulator, could increase the risk of hypotension

          -  Patient has evidence of severe or active end-organ damage attributable to diabetes

          -  Patient has severe renal insufficiency, has undergone renal transplantation, or has
             planned renal transplantation

          -  Other exclusion criteria per protocol
Clinical trial NCT02906683 (phase 2, status: completed)
Conditions: stress urinary incontinence
ICD codes: N39.41, N39.46, N39.490, N39.491, N39.492, R32, R39.81
Drugs: tas-303, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior
             to study entry

          -  Patient has at least 1 incontinence episodes per day, and urinary diurnal frequency of
             10 or less per day and nocturia of 2 or less per day.

          -  Patient is positive in 1-hour pad weight test

        Exclusion Criteria:

          -  Patient has predominant or primary urge incontinence according to investigator
             judgment

          -  Patient had a prior surgical SUI treatment

          -  Patient is diagnosed stageII or more of Pelvic Organ Prolapse

          -  Patient has symptoms of Urinary tract infection (UTI)

          -  Patient is positive pregnancy test

          -  Patient has on physical examination, neurological and/or vaginal examination results
             which, in the opinion of the investigator, should exclude the subject.
Clinical trial NCT02910050 (phase 2, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bicalutamide, aromatase inhibitor
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically confirmed estrogen receptor positive, androgen positive
             and HER2 negative breast cancer

          -  Metastatic or unresectable locally advanced disease

          -  Age over 18 years

          -  Postmenopausal status （continuous using luteinizing hormone releasing hormone(LHRH)
             analogue is available）

          -  Patient must have disease progression after treatment of an Aromatase inhibitor.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-2

          -  Life expectancy over 3 months.

          -  Measurable disease according to RECIST version 1.1 or only bone metastasis

          -  Adequate hematological, hepatic function.

          -  Voluntarily signed and dated written informed consent prior to any study specific
             procedure.

        Exclusion Criteria:

          -  Patient with life-threatening visceral metastasis, such as extensive liver metastasis,
             brain or meningeal metastasis

          -  Concomitant diseases/conditions that is not controllable, and Any other major illness
             that, in the Investigator's judgment, will substantially increase the risk associated
             with the patient's participation in this study.

          -  History of other primary malignancy

          -  Resistant to steroidal or nonsteroidal aromatase Inhibitor
Clinical trial NCT02910102 (phase 2, status: completed)
Conditions: alzheimer's disease, dementia with lewy bodies, parkinson's disease dementia
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.83, G20
Drugs: rvt-101 35 mg, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

        Male or female subject with a clinical diagnosis of Alzheimer's disease (AD), dementia with
        Lewy bodies (DLB), or Parkinson's disease dementia (PDD).

        Mini Mental State Examination score 14 to 26 Gait impairment, as assessed by history
        gathered by the clinical investigator and quantitative measurements Subjects must be on
        stable background acetylcholinesterase inhibitor therapy

        Key Exclusion Criteria:

        History and/or evidence of any other CNS disorder that could be interpreted as a cause of
        dementia (in the opinion of the investigator) Any clinically relevant concomitant disease
        which, in the opinion of the investigator, makes the subject unsuitable for inclusion in
        the study.
Clinical trial NCT02913105 (phase 2, status: terminated)
Conditions: non-alcoholic steatohepatitis nash
ICD codes: K75.81
Drugs: lmb763, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male/female patients, 18 years or older

          -  Written informed consent

          -  Presence of NASH by histologic evidence (liver biopsy) and elevated alanine
             aminotransferase (ALT), OR phenotypic diagnosis of NASH based on elevated ALT, BMI and
             diagnosis of Type 2 diabetes mellitus

        Exclusion Criteria:

          -  Current use of obeticholic acid (OCA)

          -  New initiation GLP-1 agonists such as liraglutide, exenatide , lixisenatide,
             albiglutide or dulaglutide within 3 months of screening

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential, unless they are using highly effective methods of
             contraception during dosing and for 5 days after stopping study medication

          -  Current or history of significant alcohol consumption for a period of more than 3
             consecutive months within 1 year prior to screening

          -  Clinical evidence of hepatic decompensation or severe liver impairment

          -  Previous diagnosis of other forms of chronic liver disease

          -  Uncontrolled diabetes mellitus

          -  History or current diagnosis of ECG abnormalities

          -  Patients with contraindications to MRI imaging
Clinical trial NCT02917512 (phase 2, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: hu00701, hu007, restasis, placebo
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age over 19

          -  Corneal staining score(Oxford grading) > 2 or Schirmer test < 10mm/5min (If Schirmer
             test = 0mm/5min, Nasal stimulation schirmer test > 3mm/5min)

          -  Volunteer who went through menopause more than 1 years ago before screening or has
             surgical menopause

          -  Volunteer who has negative result of pregnancy test or use effective contraception

        Exclusion Criteria:

          -  Current or recent patients used dry eye syndrome medications (topical or systemic)
             that may affect the status

          -  The patients with systemic or ocular disorders affected the test result

          -  Being treated with systemic steroid

          -  Wearing contact lenses within 3 days of screening visit

          -  Pregnancy or Breastfeeding
Clinical trial NCT02925117 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: upadacitinib, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the
             Hanifin and Rajka criteria) and onset of symptoms at least 1 year prior to Baseline.

          -  Moderate to severe atopic dermatitis defined by an Eczema Area and Severity Index
             (EASI) ≥ 16, body surface area (BSA) ≥ 10% and an Investigators Global Assessment
             (IGA) score ≥ 3 at the Baseline visit.

          -  Documented history (within 1 year prior to the screening visit) of inadequate response
             to treatment with topical corticosteroids (TCS), or topical calcineurin inhibitors
             (TCI), or for whom topical treatments are otherwise medically inadvisable (e.g.,
             because of important side effects or safety risks).

          -  Twice daily use of an additive-free, bland emollient for at least 7 days prior to
             Baseline.

        Exclusion Criteria:

          -  Prior exposure to any systemic or topical Janus kinase (JAK) inhibitor (including but
             not limited to tofacitinib, baricitinib, ruxolitinib, and filgotinib).

          -  Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI),
             prescription moisturizers or moisturizers containing additives such as ceramide,
             hyaluronic acid, urea, or filaggrin within 10 days prior to the Baseline visit.

          -  Prior exposure to dupilumab or exposure to systemic therapies for AD including
             corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4
             (PDE4)-inhibitors and mycophenolate mofetil within 4 weeks prior to Baseline.

          -  Prior exposure to any investigational systemic treatment within 30 days or 5
             half-lives (whichever is longer) of the Baseline visit or is currently enrolled in
             another clinical study.
Clinical trial NCT02927184 (phase 2, status: completed)
Conditions: hyperlipidemia, nafld
ICD codes: E78.2, E78.49, E78.5
Drugs: vk2809, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Minimum of 10% liver fat as assessed by MRI - Proton Density Fat Fraction

          2. Fasting serum LDL-C >130 mg/dL at screening, >110 mg/dL on lipid lowering medications

          3. Any one of the following:

               1. Triglycerides ≥150 mg/dL or receiving prescription medication for elevated
                  triglycerides.

               2. Systolic blood pressure >130 mmHg or diastolic blood pressure ≥85 mmHg or
                  receiving prescription medication for hypertension.

               3. Waist circumference >40 inches (men) or >35 inches (women)

          4. Body mass index (BMI) 18.50 - 40.00 kg/m2 inclusive at screening

          5. Provide a personally-signed and dated informed consent document

        Exclusion Criteria:

          1. Females of childbearing potential and males unwilling to use barrier birth control
             method (condom) throughout the study

          2. Resting 12-lead ECG showing QTc >450 msec, any tachyarrhythmia or morphology change,
             or any other clinically significant abnormality

          3. Cardiovascular event requiring hospitalization in the past year

          4. History or presence of thyroid disorder

          5. History of malignancy in past 5 years

          6. LDL-C ≥190 mg/dL or familial hypercholesterolemia

          7. Significant hepatic or renal function test abnormalities
Clinical trial NCT02928393 (phase 2, status: terminated)
Conditions: stroke
ICD codes: G46.4, G46.3, Z82.3
Drugs: basmisanil, placebo
SMILES: CC1=C(COC2=CC=C(C=N2)C(=O)N2CCS(=O)(=O)CC2)C(=NO1)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low participant enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Radiologic assessment confirming an acute middle cerebral artery ischemic stroke

          -  Index stroke occurred within the past 3-4 days

          -  Inpatient males and females

          -  Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (</=) 35

          -  Sufficient speech, vision and hearing to participate in study evaluations

        Exclusion Criteria:

          -  NIHSS greater than (>) 20

          -  Severe aphasia that prevents a participant from following directions in rehabilitation

          -  Significant deficit from prior strokes or pre-existing motor deficit

          -  History of epilepsy, neurosurgery, severe head trauma or central nervous system
             infections that have residual symptomatology or have required treatment in the last 12
             months

          -  Known or suspected clinical seizure post-index stroke

          -  History of pre-existing dementia or use of medications for dementia

          -  History of clinically significant pre-existing psychiatric conditions within 12 months
             prior to stroke

          -  Due to undergo carotid surgery within the next 4 months

          -  Enrollment/participation in any interventional study (clinical trial) involving an
             investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6
             times the half-life (whichever is longer)

          -  Clinically relevant medical conditions that would likely interfere with the study
             conduct and scheduled assessments

          -  Contraindication to magnetic resonance imaging (MRI) or conditions which render
             interpretation of MRI difficult
Clinical trial NCT02931253 (phase 2, status: terminated)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    recruitment issue: enrollment expectation not met
  
Eligibility criteria:

        Inclusion Criteria:

          -  All individuals diagnosed with Atrial Fibrillation and choosing to undergo a rhythm
             control strategy at Robert Packer Hospital with a BMI ≥ 27 will be eligible for the
             study. All subjects must be able to understand and willing to sign a written informed
             consent document.

        Exclusion Criteria:

          -  Individuals who are already taking metformin or other antidiabetic medications
             including insulin, have a diagnosis of diabetes, have a known allergy or FDA-labeled
             contraindication to taking metformin, eGFR below 30 mL/min per 1.73 m2 or other
             clinical diagnosis of advanced renal disease,, have acute or chronic metabolic
             acidosis (serum bicarbonate <22 mEq/L), have a history of significant alcohol use (>2
             drinks/day on average), have a history of hepatic dysfunction (serum bilirubin 1.5X
             greater than the upper limit of normal), have a history of New York Heart Association
             (NYHA) Class III or IV heart failure, or are pregnant will be excluded from the trial.
Clinical trial NCT02931838 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: bms-986165, placebo for bms-986165
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male and female, ages 18 to 70 years

          -  Diagnosis of plaque psoriasis for 6 months

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test, must not be pregnant, lactating, breastfeeding or planning pregnancy

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment plus 5 half-lives of the
             study drug plus 90 days.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Blood transfusion within 4 weeks of study drug administration

          -  Inability to tolerate oral medication

          -  Positive hepatitis-B (HBV) surface antigen

          -  Positive hepatitis-C (HCV) antibody

          -  Any history or risk for tuberculosis (TB)

          -  Any major illness/condition or evidence of an unstable clinical condition

          -  Chest X-ray findings suspicious of infection at screening

          -  has received ustekinumab, secukinumab or ixekizumab within 6 months of first
             administration of study medication

          -  Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first
             administration of study medication

          -  Has received Rituximab within 6 months of first administration of study medication

          -  Topical medications/treatments for psoriasis within 2 weeks of the first
             administration of any study medication

          -  Any systemic medications/treatments for psoriasis within 4 weeks of the first
             administration of any study medication

        Other protocol defined inclusion/exclusion criteria could apply